Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies

Table 1

Combinations of autoantibodies evaluated as diagnostic measures.

Antibody specificity	Number of patients	Tumor type	Specificity/Sensitivitiy	Ref.
PIM1, MAPKAPK3, ACVR2B	114	Colon cancer	74/83	[28]
ASB-9, SERAC1, RELT	87	Breast cancer	100/80	[29]
PPIA, PRDX2, FKBP52, MUC-1, HSP60	142	Breast cancer	73/85	[30]
Calnuc, p53, Cyclin D1, Cyclin B1, myc	447	Mixed	59/62	[31]
myc, p53, Cyclin B1, p62, Koc, IMP1, Survivin	976	Mixed	50/91	[22]
CCCAP, HDAC5, p53, NMDAR, NY-CO-16	94	Colon cancer	59/78	[32]
SEREX clones (𝑁=6)	48	Colon cancer	96/92	[33]
SEREX clones (𝑁=10)	77	HCC	87/66	[34]
Imp1, p62, Koc, p53, myc, Cyclin B1, Survivin, p16	142	HCC	50/60	[35]
SEREX clones (𝑁=80)	39	Head and neck cancer	90/80	[36]
O-glycopeptides	56	Mixed	85/25	[37]
Nucleophosmin, Cathepsin D, p53, SSX	125	Ovarian cancer	NN	[38]
Autoantibodies to MIAPACA cell line	238	Pancreatic cancer	80/93	[39]
Phage display clones (𝑁=22)	119	Prostate cancer	88/82	[40]
p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2, MUC1	97	Breast cancer	85/64	[17]
p53, NY-ESO-1, CAGE; GBU4-5, Annexin 1	626	Lung cancer	90/40	[41]